These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients. Park JS; Jung HH; Yang WS; Kim SB; Min WK; Chi HS Nephrol Dial Transplant; 2000 Nov; 15(11):1835-40. PubMed ID: 11071974 [TBL] [Abstract][Full Text] [Related]
9. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295 [TBL] [Abstract][Full Text] [Related]
10. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735 [TBL] [Abstract][Full Text] [Related]
11. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Sumino H; Ichikawa S; Sawada Y; Sakamoto H; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M Thromb Res; 2005; 115(5):359-66. PubMed ID: 15733968 [TBL] [Abstract][Full Text] [Related]
12. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats]. Gao H; Xi S; Xu L Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689 [TBL] [Abstract][Full Text] [Related]
13. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Schlegel W; Petersdorf LI; Junker R; Schulte H; Ebert C; Von Eckardstein A Clin Endocrinol (Oxf); 1999 Nov; 51(5):643-51. PubMed ID: 10594527 [TBL] [Abstract][Full Text] [Related]
14. Circulating concentrations of hemostatic factors and two "steroid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease. Pripp U; Schenck-Gustafsson K; Landgren BM; Carlström K Scand J Clin Lab Invest; 2004; 64(7):659-65. PubMed ID: 15513323 [TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Yilmazer M; Fenkci V; Fenkci S; Sonmezer M; Aktepe O; Altindis M; Kurtay G Maturitas; 2003 Dec; 46(4):245-53. PubMed ID: 14625121 [TBL] [Abstract][Full Text] [Related]
16. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658 [TBL] [Abstract][Full Text] [Related]
17. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Norris LA; Bonnar J Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312 [TBL] [Abstract][Full Text] [Related]